Navigation Links
Pneumonia Drug Promising Against Form of Muscular Dystrophy
Date:11/12/2009

In studies with mice, pentamidine combats genetic defects that lead to myotonic dystrophy

THURSDAY, Nov. 12 (HealthDay News) -- Researchers report that a drug used to treat pneumonia might serve as an effective treatment against a type of muscular dystrophy.

They tested the drug pentamidine in mice and found that it appears to combat genetic defects that lead to type 1 myotonic dystrophy, one of nine types of muscular dystrophy. The muscle-wasting condition is also known as DM1 and Steinart's disease.

The levels used in mice would be poisonous in humans, but University of Oregon chemist J. Andrew Berglund, whose lab tested the drug, said it could be modified.

Pentamidine is approved to treat several conditions, including a severe type of pneumonia in people with compromised immune systems, some yeast infections and sleeping sickness.

"Pentamidine is an exciting lead compound because it is relatively easy to chemically modify, and hopefully one of these modified compounds could lead to a safe, long-term treatment for DM1 in the future," said Berglund.

The study, funded in part by the U.S. National Institutes of Health and the Muscular Dystrophy Association, was published in the Nov. 3 issue of Proceedings of the National Academy of Sciences.

More information

Learn more about muscular dystrophy from the National Institutes of Health.



--Randy Dotinga



SOURCE: University of Oregon, press release, Nov. 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Zinc Helps Elderly Ward Off Pneumonia
2. Heart attacks/pneumonia falls short of national goals
3. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
4. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
5. Pneumonia Vaccine Is Keeping Kids Healthier
6. Treating Childhood Pneumonia at Home Could Save Lives in Developing Countries
7. Childrens Hospital scientists identify possible target for prevention and treatment of pneumonia
8. Community-Based Staph Pneumonia More Common Than Thought
9. TB Drug Treatment Can Lead to Severe Pneumonia
10. Antipsychotic drugs increase risk of developing pneumonia in elderly
11. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 22, 2017 , ... The VA Maryland Health Care System ... awarded the Baltimore VA Medical Center, a division of the VA Maryland Health ... to promote waste reduction and promote recycling. Also, Practice Greenhealth has recognized ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... health science curriculum , is pleased to announce a new online course entitled ... online course provides practical insights and evidence-based strategies for achieving optimal well-being and ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... that the introduction of school choice can promote economic development in economically distressed ... that has, according to the report, contributed to the economic development of the ...
(Date:6/20/2017)... ... 2017 , ... Leading dental clinicians, Drs. Ashlyn Price, Autumn Mayers and Ron ... Anatomage systems. With advanced digital images and modeling capabilities, the dentists identify all of ... restore oral health for those who are missing teeth in Midlothian, VA. ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... years ago today, the Monterey Pop Festival opened its gates ... Francisco "Summer of Love."  To celebrate the anniversary, Northern Light® ... market research portals that it will begin delivering to customers ... "Summer of Love (For Our Customers)."  ... Northern Light ...
(Date:6/14/2017)... WINSTON-SALEM, N.C. , June 14, 2017  In ... the Creative Startups pitch competition and came ... virtual reality platform is described by Forbes as "entering ... the American Medical Association as teaching "empathy to medical ... success, the startup was recently named a finalist for ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
Breaking Medicine Technology: